# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: David Hume (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN012-SYN-TD
- Date: 1775-07-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Fiona Gallacher, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review four weeks after sigmoid colectomy. **S**

## History of present illness

Mr. Hume returns four weeks after laparoscopic sigmoid colectomy with primary anastomosis. The liver MRI before surgery showed that the 9 mm lesion is a hemangioma, with no metastases. He went home on the third day. His stools are now formed, once or twice a day, with no blood, and his wounds have healed. He walks 20 minutes a day and is less tired since the two iron infusions. The pathology shows a pT3 N1a adenocarcinoma, with 1 of 22 lymph nodes involved, clear margins, and no lymphovascular or perineural invasion: stage IIIB. Dr. Mehta has advised three months of adjuvant CAPOX, starting next week, and sent a DPYD genotype test before the first capecitabine dose. He has been offered genetic counseling. **S**

| Element | Detail |
|---|---|
| Interval change | Colectomy four weeks ago; home on the third day |
| Bowel function | Formed stools once or twice a day; no bleeding |
| Pathology | pT3 N1a (1 of 22 nodes), R0, stage IIIB |
| Function | Walking 20 minutes a day; energy improving |
| Plan from oncology | CAPOX for three months from next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever |
| Gastrointestinal | Negative | Formed stools; no bleeding, pain, or urgency |
| Integumentary | Negative | Wounds healed |
| Neurological | Negative | No numbness or tingling of the hands or feet |
| Psychiatric | Negative | Mood good; PHQ-2 score 1; coping well |

5 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 82.5 kg; BMI 26 kg/m². All vital signs are synthetic.

CEA: 2.2 ng/mL; Hemoglobin: 12.4 g/dL (low); MCV: 82 fL; White cell count: 6.8 10*3/uL; Absolute neutrophil count: 4.1 10*3/uL; Platelets: 312 10*3/uL; Ferritin: 186 ng/mL; Transferrin saturation: 24%; Creatinine: 0.96 mg/dL; eGFR: 88 mL/min/1.73 m²; ALT: 20 U/L; Total bilirubin: 0.5 mg/dL; Albumin: 3.9 g/dL; PHQ-2: 1. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.6 g/dL (low) at baseline, 12.4 g/dL (low) at this visit **S**
- MCV: 74 fL (low) at baseline, 82 fL at this visit **S**
- White cell count: 7.4 10*3/uL at baseline, 6.8 10*3/uL at this visit **S**
- Platelets: 438 10*3/uL (high) at baseline, 312 10*3/uL at this visit **S**
- Ferritin: 9 ng/mL (low) at baseline, 186 ng/mL at this visit **S**
- Transferrin saturation: 6% (low) at baseline, 24% at this visit **S**
- Creatinine: 0.94 mg/dL at baseline, 0.96 mg/dL at this visit **S**
- eGFR: 91 mL/min/1.73 m² at baseline, 88 mL/min/1.73 m² at this visit **S**
- ALT: 22 U/L at baseline, 20 U/L at this visit **S**
- Albumin: 3.8 g/dL at baseline, 3.9 g/dL at this visit **S**
- PHQ-2: 1 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, better color |
| Abdomen | Port-site scars healed; soft, non-tender; no hernia |
| Neurological | Baseline before oxaliplatin: light touch, vibration, and proprioception normal in hands and feet; ankle reflexes present |
| Skin | Palms and soles normal before capecitabine |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Resected stage IIIB sigmoid adenocarcinoma, before adjuvant therapy** (C18.7). Curative resection with clear margins. CEA has fallen from 6.4 to 2.2 ng/mL, which supports complete resection. Low-risk stage III (T3 N1), for which three months of CAPOX is the evidence-based choice. Kidney and liver function allow full doses (eGFR 88). **S**
   - CAPOX from next week through the oncology team, if the DPYD genotype shows no decreased-function variant.
   - Call the oncology 24-hour line for a temperature of 38.0 °C or higher; avoid acetaminophen before checking a temperature.
   - Primary care follows neuropathy, blood counts, mood, and survivorship planning.
2. **Iron deficiency anemia, iron replete** (D50.0). Six weeks after intravenous iron, ferritin is 186 ng/mL and transferrin saturation 24 percent. Hemoglobin has risen from 10.3 to 12.4 g/dL and should continue to recover now the bleeding source is removed. **S**
   - No further iron.
   - Blood counts with chemotherapy and at the end of treatment.
3. **Hemangioma of the liver** (D18.03). Benign incidental finding on MRI; not a metastasis. **S**
   - No dedicated follow-up; it will be seen on surveillance CT.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CEA after resection | Every 3 to 6 months for 2 years | Completed today | 2.2 ng/mL, normal, down from 6.4 before surgery |
| Laboratory | Blood count and iron studies 6 to 8 weeks after intravenous iron | Once after infusion | Completed today | Hemoglobin 12.4 g/dL, MCV 82 fL; ferritin 186 ng/mL, transferrin saturation 24 percent; neutrophils 4.1 and platelets 312 before chemotherapy |
| Laboratory | Kidney and liver function before chemotherapy | Before each cycle (oncology) | Completed today | Creatinine 0.96 mg/dL, eGFR 88; ALT 20 U/L, bilirubin 0.5 mg/dL, albumin 3.9 g/dL |
| Survey | Distress and depression screen (PHQ-2) | At each follow-up visit | Completed today | PHQ-2 score 1; coping well |
| Survey | Distress screen missed at the diagnosis visit | At each follow-up visit | Deferred | Missed at the visit three weeks after presentation, a deviation from the protocol. Today's screen is negative and he reports coping well, so no harm is evident; the screen is now on his visit checklist |
| Imaging | MRI of the liver | Once, for the indeterminate CT lesion | Up to date | Done before surgery: hemangioma; no metastases |
| Imaging | CT of the chest, abdomen, and pelvis | Every 6 to 12 months for 5 years | Due | First surveillance scan about six months after surgery |
| Examination | History and examination, wound and bowel function | Every 3 to 6 months for 2 years | Completed today | Wounds healed; formed stools; no ostomy |
| Examination | Peripheral neuropathy baseline | Before and at every visit during and after oxaliplatin | Completed today | Normal sensation and reflexes before the first dose |
| Medication safety | DPYD genotype before capecitabine | Once, before the first dose | Ordered | Sent by the oncology team; the result will be reviewed before cycle 1 |
| Referral | Genetic counseling for germline testing | At diagnosis of colorectal cancer, especially with a family history | Referred | Offered because his mother is reported to have died of a similar bowel illness; tumor mismatch-repair proficient |
| Self-management | Physical activity | Every visit | Completed today | Walking 20 minutes a day; goal of 150 minutes a week through chemotherapy |

## Goal progress

- Complete diagnosis, staging, and curative resection within six weeks of presentation. Outcome by 1775-07-13: Colonoscopy in eight days, staging complete in three and a half weeks, colectomy at five weeks. **S**
- Replete iron stores before surgery and recover hemoglobin by the postoperative review. Outcome by 1775-07-13: Ferritin 186 ng/mL and hemoglobin 12.4 g/dL four weeks after surgery, up from 9 ng/mL and 10.6 g/dL. **S**
- Complete three months of adjuvant CAPOX with neuropathy no worse than grade 1. In progress; target 1775-10-19. **S**
- Start survivorship surveillance with a written survivorship care plan. In progress; target 1775-10-19. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 4.2025 (2025), National Comprehensive Cancer Network
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (IDEA collaboration). N Engl J Med 2018;378:1177-1188 (2018), New England Journal of Medicine
- AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia (2020), American Gastroenterological Association
- CMID: Clinical Monitoring Intelligence Database, colorectal cancer and anemia monographs (2026), Aether Forge

## Follow-up

- CAPOX cycle 1 next week with the oncology team. Primary care review after the fourth cycle, with blood count, CEA, and a neuropathy check. **S**
- Next scheduled visit 1775-10-19: review two weeks after completing adjuvant CAPOX and start of survivorship surveillance. **S**
